Sign In
Buy DNLI
$19.66
+0.310 (+1.60%)
At Close: Jun 03, 2026
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Rating of “Buy” from Analysts
02:18am, Friday, 26'th Dec 2025
Shares of Denali Therapeutics Inc. (NASDAQ: DNLI - Get Free Report) have been given an average recommendation of "Buy" by the sixteen ratings firms that are currently covering the firm, MarketBeat rep
Biggest Stock Movers Today, Dec. 10: PLAB, AVAV, & More
04:38pm, Wednesday, 10'th Dec 2025
Wednesday brought gains for major stock benchmarks. The Federal Reserve cut interest rates but signaled a slowing in expected future reductions.
Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment
02:47pm, Wednesday, 10'th Dec 2025
Denali Therapeutics Inc. is maintained at a Strong Buy rating, driven by progress in its MPS II [Hunter Syndrome] program with tividenofusp alfa. Despite discontinuing ALS efforts, DNLI's BLA for tivi
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
12:14am, Wednesday, 10'th Dec 2025
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
04:01pm, Tuesday, 09'th Dec 2025
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $200 million of shares of its common stock and,
Denali Enters Into a $275M Funding Deal With Royalty Pharma
11:01am, Friday, 05'th Dec 2025
DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.
Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript
02:58am, Friday, 05'th Dec 2025
Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
07:10am, Thursday, 04'th Dec 2025
NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic roya
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
07:00am, Thursday, 04'th Dec 2025
SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royal
Edgestream Partners L.P. Acquires New Stake in Denali Therapeutics Inc. $DNLI
04:30am, Wednesday, 03'rd Dec 2025
Edgestream Partners L.P. bought a new position in shares of Denali Therapeutics Inc. (NASDAQ: DNLI) during the undefined quarter, according to the company in its most recent disclosure with the SEC. T
Denali: Regulatory Delay Is A Strategic Opportunity
08:09am, Tuesday, 02'nd Dec 2025
Denali Therapeutics (DNLI) is transitioning from a clinical-stage to a commercial-stage biotech, leveraging its innovative blood-brain barrier Transport Vehicle platform. DNLI's financials reflect inc
Creative Planning Buys 27,114 Shares of Denali Therapeutics Inc. $DNLI
04:10am, Tuesday, 02'nd Dec 2025
Creative Planning increased its stake in shares of Denali Therapeutics Inc. (NASDAQ: DNLI) by 88.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securiti
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Rating of “Buy” from Brokerages
01:46am, Monday, 01'st Dec 2025
Denali Therapeutics Inc. (NASDAQ: DNLI - Get Free Report) has been assigned a consensus recommendation of "Buy" from the sixteen ratings firms that are currently covering the stock, MarketBeat.com rep
Denali Therapeutics Inc. (DNLI) Presents at Jefferies London Healthcare Conference 2025 Transcript
03:03am, Saturday, 22'nd Nov 2025
Denali Therapeutics Inc. ( DNLI ) Jefferies London Healthcare Conference 2025 November 18, 2025 7:30 AM EST Company Participants Ryan Watts - Co-Founder, President, CEO & Director Alexander Schuth - C
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug
02:26pm, Friday, 07'th Nov 2025
Denali's Q3 loss widens year over year as expenses rise, while the FDA delays its review of the firm???s key Hunter syndrome therapy to 2026.
